Earlier, More Sensitive, Diagnostic Accuracy
Advancements in molecular biology have enabled a deeper scientific understanding of circulating EV profiles that will serve as a foundation for development of more effective diagnostic tools. Ongoing research continues to elucidate specific micro RNA and protein contents of EVs that correlate with specific disease states and severity. The same EV purification and characterization technology that EV Biologics utilizes for quality management will enable the development of earlier and more accurate diagnostic tests. Isolation and characterization of circulating EVs from readily accessible body fluids such as serum, plasma, CSF,
urine or saliva will provide clinical researchers with the means to perform liquid biopsies that avoid the morbidity of surgical biopsy. Future EV-based diagnostics will facilitate early detection and staging of diseases such as pancreatic cancer, dementia or diabetes, which may significantly improve their prognosis. In order to fulfill their commitment to the improvement of health and wellness, EV Biologics intends to build libraries of EV profiles associated with different disease states using its advanced EV isolation and characterization technology. to serve as the foundation for specific diagnostic assays for clinical use.
Pathway to Clinical Development of Exosomes
Development of Precision Biopharmaceuticals
As a new class of biologic therapeutics, EVs have significant advantages over traditional small molecule drugs. One major difference is that they are naturally occurring and have demonstrated an excellent safety profile in both preclinical studies and clinical use. Another important advantage of EVs as pharmacologic agents is the breadth of their cargo, which enables them to target multiple receptors and signaling pathways within the cell to achieve multiple therapeutic effects. Stem cell EVs have innate properties that could benefit numerous autoimmune, inflammatory, degenerative, metabolic, traumatic and neoplastic diseases.
The next incremental leap in biopharmaceutical technology is engineering specific biological properties by optimizing exosome protein and RNA contents for specific clinical applications. Employing the expertise of molecular cell biologists, biological chemists and regenerative physicians, EV Biologics is developing the next generation of vaccines, therapeutics and cures based on a multifunctional EV platform. Advancement toward clinical use begins with GMP bioprocessing, stringent quality management and an immaculate safety record for innovative EV solutions to pressing clinical challenges.